ASH 2014 | Recent investigational advances in mantle cell lymphoma treatment

Name: Recent investigational advances in mantle cell lymphoma treatment
Uploaded: 2014-12-05T00:00:00Z
Duration: 2 min 9 s
Description: Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the treatment of patients with mantle cell lymphoma (MCL), including the phase 2 SPRINT study of lenalidomide versus investigator’s choice in relapsed or refractory MCL and a phase 2 study of lenalidomide plus rituximab as initial treatment in MCL.

Simon Rule • 5 Dec 2014

ASH 2014

Mantle Cell Lymphoma Lenalidomide

SPRINT

Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the treatment of patients with mantle cell lymphoma (MCL), including the phase 2 SPRINT study of lenalidomide versus investigator’s choice in relapsed or refractory MCL and a phase 2 study of lenalidomide plus rituximab as initial treatment in MCL.